<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059123</url>
  </required_header>
  <id_info>
    <org_study_id>P071207</org_study_id>
    <secondary_id>2008-006794-32</secondary_id>
    <nct_id>NCT01059123</nct_id>
  </id_info>
  <brief_title>Short Course of Amoxicillin for Erysipelas</brief_title>
  <acronym>SHARE</acronym>
  <official_title>Randomized Non Inferiority Study Comparing Short Course of Oral Amoxicillin to One of the Usual Treatments of Lower Leg Erysipelas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Société de Dermatologie Française</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The propose of this study is to determine whether a 6-day duration of oral amoxicillin&#xD;
      treatment of erysipelas is non-inferior to a 14-day standard duration intravenous then oral&#xD;
      amoxicillin regimen. This trial will be open but evaluation will be perform by a blind&#xD;
      evaluator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To fight against increasing rate of bacterial resistance to antibiotics, several studies have&#xD;
      demonstrated efficacy of short antibiotic course in e.g. acute streptococcal tonsillitis,&#xD;
      community acquired pneumonia, and urinary tract infection. Erysipelas is an acute&#xD;
      dermo-hypodermal infection due to streptococcus. To date no resistance of theses bacteria to&#xD;
      amoxicillin was described. The diagnosis of erysipelas is clinical. Thus, short course of&#xD;
      antibiotic is a good regimen to test in erysipelas treatment. To date there is no controlled&#xD;
      trial concerning efficacy of oral amoxicillin in erysipelas treatment. Expected advantages of&#xD;
      the demonstration of the non inferiority of a short and oral amoxicillin treatment in&#xD;
      erysipelas are: reduction of antibiotic selective pressure, cost, adverse events caused by&#xD;
      infusion and hospitalisation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient number of inclusion&#xD;
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate defined as body temperature ≤ 37,5°and disappearance of the cutaneous plaque (score=o)</measure>
    <time_frame>Day 30 ± 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to obtain disappearance of fever and local signs</measure>
    <time_frame>up to day 30 ± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>end of treatment to day 30± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>day 30± 5 to day 95± 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>30 days ± 5</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Erysipelas</condition>
  <arm_group>
    <arm_group_label>1:Short treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2:Usual treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>50 mg/kg/24H ; Per Os ; 3 times/day 6 days</description>
    <arm_group_label>1:Short treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.</description>
    <arm_group_label>2:Usual treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females ≥ 18 years of age&#xD;
&#xD;
          -  First episode of erysipelas of a lower leg defined as&#xD;
&#xD;
               -  acute well delineate inflammation than had lasted less than 5 days&#xD;
&#xD;
               -  T°≥ 38°5 at least once during the past 5 days or chills.&#xD;
&#xD;
               -  Score ≥3 : oedema, erythema, pain each scored from 0 to 3 : 0= none, 1= moderate,&#xD;
                  3= severe&#xD;
&#xD;
          -  Written informed consent provided by the patient&#xD;
&#xD;
          -  available health insurance&#xD;
&#xD;
          -  accept conditions of the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Erysipelas for more than 5 days&#xD;
&#xD;
          -  Score &lt; 3&#xD;
&#xD;
          -  Septic shock&#xD;
&#xD;
          -  Clinical signs of necrotizing cellulitis or fasciitis, bullous lesions related to&#xD;
             necrosis, purpuric lesions or superficial cutaneous necrosis.&#xD;
&#xD;
          -  Past history of erysipelas of the same lower leg&#xD;
&#xD;
          -  Erysipelas not on the lower leg&#xD;
&#xD;
          -  Bilateral erysipelas&#xD;
&#xD;
          -  Bite occuring during the preceding 7 days.&#xD;
&#xD;
          -  Diabetic foot&#xD;
&#xD;
          -  patients who have previously received systemic antibiotherapy within the last 5 days&#xD;
             (except one or two doses within last 24 hours)&#xD;
&#xD;
          -  History of any hypersensitivity or allergic reaction to beta-lactam drugs&#xD;
&#xD;
          -  Known renal or Hepatic failure&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Female patients who are pregnant, lactating (breast milk feeding), or who are of child&#xD;
             bearing potential and not using an acceptable method of birth control&#xD;
&#xD;
          -  Impossibility to stop immunosuppressive treatment, systemic corticosteroids or&#xD;
             nonsteroidal anti-inflammatory drugs.&#xD;
&#xD;
          -  Severe gastrointestinal disease, dysphagia or any pathology preventing oral&#xD;
             administration of treatment.&#xD;
&#xD;
          -  Denied to sign written informed consent&#xD;
&#xD;
          -  Unable or unwilling to adhere to the study-specified procedures and restrictions&#xD;
&#xD;
          -  Evolutive cancer under treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier CHOSIDOW, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Henri Mondor - Service de dermatologie</name>
      <address>
        <city>Créteil</city>
        <state>Ile de France</state>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>January 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2010</study_first_posted>
  <last_update_submitted>February 6, 2014</last_update_submitted>
  <last_update_submitted_qc>February 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amoxicillin</keyword>
  <keyword>Erysipelas</keyword>
  <keyword>Short course</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erysipelas</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

